Biogen Walloped Wall Street's First Quarter Views; Here's What Happened
Technology Biogen Had A Nearly Perfect Sales Sweep, But One Beat Really Stood Out Licensing ALLISON GATLIN Updated 04:04 PM ET 04/29/2026 Biogen (BIIB) obliterated Wall Street's first-quarter expectations Wednesday, helped by a nearly perfect sales beat sweep for its growth products. The most notable beat, according to RBC Capital Markets analyst Brian Abrahams, was from its Alzheimer's treatment, Leqembi. Sales of Leqembi, developed with Japan's Eisai, grew 74% to $168 million.
- ▪Technology Biogen Had A Nearly Perfect Sales Sweep, But One Beat Really Stood Out Licensing ALLISON GATLIN Updated 04:04 PM ET 04/29/2026 Biogen (BIIB) obliterated Wall Street's first-quarter expectations Wednesday, helped by a nearly perfe
- ▪The most notable beat, according to RBC Capital Markets analyst Brian Abrahams, was from its Alzheimer's treatment, Leqembi.
- ▪Sales of Leqembi, developed with Japan's Eisai, grew 74% to $168 million.
Opening excerpt (first ~120 words) tap to expand
Technology Biogen Had A Nearly Perfect Sales Sweep, But One Beat Really Stood Out Licensing ALLISON GATLIN Updated 04:04 PM ET 04/29/2026 Biogen (BIIB) obliterated Wall Street's first-quarter expectations Wednesday, helped by a nearly perfect sales beat sweep for its growth products. The most notable beat, according to RBC Capital Markets analyst Brian Abrahams, was from its Alzheimer's treatment, Leqembi. Sales of Leqembi, developed with Japan's Eisai, grew 74% to $168 million.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Investor's Business Daily.
Discussion
0 commentsMore from Investor's Business Daily
